('ai', 16);('medicare', 7);('draft pre-print', 6);('richard h. mcadams', 4);('n =', 4);('alkermes plc', 4);('cms', 4);('legislation', 4);('cass r. sunstein', 4);('expressive powers', 4);('humans', 3);('pharmaceutical companies', 3);('expressive function', 3);('univ', 3);('stanford', 2);('large language model', 2);('u.s.', 2);('congressional bills', 2);('provide', 2);('frank pasquale', 2);('john nay', 2);('informs code', 2);('legal informatics approach', 2);('aligning artificial intelligence', 2);('northwestern journal', 2);('intellectual', 2);('forthcoming', 2);('ssrn', 2);('expressive', 2);('theory', 2);('official title', 2);('official subjects', 2);('answer', 2);('explanation', 2);('confidence', 2);('gpt', 2);('unmet needs', 2);('medicaid', 2);('prescription drug benefit', 2);('medicare negotiation', 2);('competitive licensing', 2);('significant amount', 2);('penn', 2);('rev.', 2);('mcadams', 2);('contact', 1);('john.j.nay @ gmail.com', 1);('article', 1);('personal views', 1);('brooklyn', 1);('investment group', 1);('financial advice', 1);('large language', 1);('lobbyists john j. nay', 1);('codex', 1);('legal informatics january', 1);('abstract', 1);('proof -of-concept', 1);('activities .1', 1);('openais', 1);('specific public companies', 1);('confidence levels', 1);('model deems', 1);('model drafts', 1);('ground -truth labels', 1);('mo st', 1);('common outcome', 1);('openai gpt', 1);('language tasks', 1);('novem', 1);('results s uggest', 1);('large language models', 1);('natural language understanding capabilities', 1);('societal -ai alignment', 1);('open -source code', 1);('//github.com/johnnay/llm -lobbyist', 1);('introduction setting', 1);('new legal precedent', 1);('agency rules', 1);('judicial opinion', 1);('democratic governmental systems', 1);('huma n values.2', 1);('artificial instrumental power', 1);('intelligence', 1);('ambitious goal', 1);('b e', 1);('legal concepts', 1);('positive implications', 1);('normative stance', 1);('law encapsulates human', 1);('humans value', 1);('rich set', 1);('incomplete specifications', 1);('collective human expectations ,5', 1);('generalizable precedents', 1);('model training', 1);('societal goals', 1);('goal specification', 1);('int erpretation methods', 1);('societal knowledge', 1);('critical role', 1);('human s.', 1);('paper explores', 1);('ii', 1);('example', 1);('gpt as lobbyist', 1);('large language model s', 1);('summarize', 1);('bill summaries', 1);('context window', 1);('th e', 1);('original bill summary', 1);('companys description', 1);('confidence level', 1);('laws', 1);('robotics', 1);('defending', 1);('expertise', 1);('age', 1);('machines', 1);('limits', 1);('legal automation', 1);('george washington', 1);('review', 1);('information sour ce', 1);('public attitudes', 1);('attitudinal theory', 1);('focal', 1);('bill { official_title }', 1);('bill { summary_text }', 1);('bill { subjects } company name { company_name } company business description { business_descripti', 1);('business description', 1);('sec form', 1);('models predictions', 1);('potential impacts', 1);('sec', 1);('{ official_title }', 1);('official summary', 1);('{ summary_text }', 1);('{ subjects } company name', 1);('{ company_name } company business description', 1);('{ business_description }', 1);('i n', 1);('step -by-step reasoning', 1);('low confidence', 1);('federal congressional bill', 1);('accuracy o f', 1);('state -of-the-art', 1);('natural language', 1);('benchmark tasks6', 1);('november', 1);('confidence assessments', 1);('s confidence', 1);('small number', 1);('percy liang', 1);('holistic evaluation', 1);('language', 1);('arxiv preprint', 1);('overall output', 1);('confidence score', 1);('promp t', 1);('explana tion', 1);('relevance decision', 1);('model output', 1);('yes', 1);('commercializes products', 1);('additionally', 1);('centers', 1);('service s', 1);('example letter', 1);('dear', 1);('sponsor', 1);('bill', 1);('global biopharmaceutical company', 1);('scientific expertise', 1);('proprietary te chnologies', 1);('commercialize pharmaceutical products', 1);('address unmet', 1);('medical needs', 1);('major therapeutic areas', 1);('important step', 1);('c enters', 1);('m edicare beneficiaries', 1);('alkermes', 1);('commercialize products', 1);('aristada', 1);('vivitrol', 1);('i nclude provisions', 1);('additional incentives', 1);('sincerely', 1);('counsel', 1);('iii', 1);('problem for ai alignment', 1);('t wo potential upsides', 1);('human time spen t', 1);('rote tasks', 1);('cost s', 1);('non -profit organizations', 1);('individual citizens', 1);('influential th', 1);('natural -language', 1);('obvious potential downsides', 1);('instrumental power', 1);('public policy', 1);('actual views', 1);('slow drift', 1);('othe rwise emergent phenomena', 1);('public policies', 1);('traditional human-driven policy activities', 1);('regulation', 1);('l egislation', 1);('world knowledge', 1);('human values', 1);('e mployment discrimination', 1);('lgbt', 1);('communicate pervasive attitudes', 1);('such employment practices.8', 1);('endangered species', 1);('special salience', 1);('certain conception', 1);('human beings', 1);('inappropriate valuation', 1);('citizen beliefs', 1);('-best source', 1);('citizen attitudes', 1);('local level', 1);('mainstream issues', 1);('trustworthy information', 1);('legislators risk', 1);('public opini', 1);('incommensurability', 1);('valuation', 1);('mich. l. rev', 1);('richard h. pildes', 1);('reinventing', 1);('regulatory', 1);('u. cm', 1);('l. rev', 1);('dhammika dharmapala', 1);('condorcet', 1);('theorem', 1);('informative', 1);('american law', 1);('economics review', 1);('harv', 1);('hereinafter mcad', 1);('law ]', 1);('handy aggregation', 1);('expert opinion', 1);('polls reliability.10', 1);('ag ency rule', 1);('risk preferences', 1);('risk tradeoff', 1);('cell phones', 1);('traffic accident.11', 1);('society -wide tradeoffs', 1);('sociological process', 1);('cultural process', 1);('subsequent implementation', 1);('domain experts', 1);('systems need', 1);('societal alignment', 1);('legitimate societal -ai alignment process12', 1);('tec', 1);